BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11713805)

  • 1. Technology evaluation: leukemia therapy, University of Pennsylvania.
    Orr RM
    Curr Opin Mol Ther; 1999 Jun; 1(3):399-403. PubMed ID: 11713805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oligonucleotide therapeutics: clothing the emperor.
    Gewirtz AM
    Curr Opin Mol Ther; 1999 Jun; 1(3):297-306. PubMed ID: 11713794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense oligodeoxynucleotides for the treatment of chronic myelogenous leukemia: are they still a promise?
    de Fabritiis P; Calabretta B
    Haematologica; 1995; 80(4):295-9. PubMed ID: 7590496
    [No Abstract]   [Full Text] [Related]  

  • 4. Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: a pilot study.
    Luger SM; O'Brien SG; Ratajczak J; Ratajczak MZ; Mick R; Stadtmauer EA; Nowell PC; Goldman JM; Gewirtz AM
    Blood; 2002 Feb; 99(4):1150-8. PubMed ID: 11830460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxetane modified, conformationally constrained, antisense oligodeoxyribonucleotides function efficiently as gene silencing molecules.
    Opalinska JB; Kalota A; Gifford LK; Lu P; Jen KY; Pradeepkumar PI; Barman J; Kim TK; Swider CR; Chattopadhyaya J; Gewirtz AM
    Nucleic Acids Res; 2004; 32(19):5791-9. PubMed ID: 15514112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Technology evaluation: ISIS-3521.
    Li K; Zhang J; Sirois P; Hu Y
    Curr Opin Mol Ther; 1999 Jun; 1(3):393-8. PubMed ID: 11713804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.
    Brignole C; Pastorino F; Marimpietri D; Pagnan G; Pistorio A; Allen TM; Pistoia V; Ponzoni M
    J Natl Cancer Inst; 2004 Aug; 96(15):1171-80. PubMed ID: 15292389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multigene targeting with antisense oligodeoxynucleotides: an exploratory study using primary human leukemia cells.
    Opalinska JB; Machalinski B; Ratajczak J; Ratajczak MZ; Gewirtz AM
    Clin Cancer Res; 2005 Jul; 11(13):4948-54. PubMed ID: 16000594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coding sequence and intron-exon junctions of the c-myb gene are intact in the chronic phase and blast crisis stages of chronic myeloid leukemia patients.
    Bussolari R; Candini O; Colomer D; Corradini F; Guerzoni C; Mariani SA; Cattelani S; Silvestri C; Pecorari L; Iacobucci I; Soverini S; Fasano T; Martinelli G; Cervantes F; Calabretta B
    Leuk Res; 2007 Feb; 31(2):163-7. PubMed ID: 16797705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
    Sun J; Wu B; Liu Q; Feng R; Liu X; Meng F; Zhou S
    Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):400-2. PubMed ID: 11877009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
    Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A DNA uptake-stimulating protein increases the antiproliferative effect of c-myb antisense oligonucleotide on leukemic cells.
    Tóth G; Schlammadinger J; Aradi J; Antal-Szalmás P; Sipka S; Balázs M; Kovács P; Fehér Z; Falus A
    Cell Biol Int; 2004; 28(11):817-23. PubMed ID: 15563404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical experience of antisense therapy to ICAM-1 in Crohn's disease.
    Yacyshyn B; Bowen-Yacyshyn MB; Shanahan W
    Curr Opin Mol Ther; 1999 Jun; 1(3):332-5. PubMed ID: 11713798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ISIS-3521. Isis Pharmaceuticals.
    Li K; Zhang J
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1454-61. PubMed ID: 11890365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2.
    Perrotti D; Cesi V; Trotta R; Guerzoni C; Santilli G; Campbell K; Iervolino A; Condorelli F; Gambacorti-Passerini C; Caligiuri MA; Calabretta B
    Nat Genet; 2002 Jan; 30(1):48-58. PubMed ID: 11753385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for higher-order structure formation by the c-myb 18-mer phosphorothioate antisense (codons 2-7) oligodeoxynucleotide: potential relationship to antisense c-myb inhibition.
    Vilenchik M; Benimetsky L; Kolbanovsky A; Miller P; Stein CA
    Antisense Nucleic Acid Drug Dev; 2001 Apr; 11(2):87-97. PubMed ID: 11334144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis.
    Olsson-Strömberg U; Aleskog A; Björnberg A; Höglund M; Simonsson B; Bengtsson M; Barbany G; Larsson R; Lindhagen E
    Anticancer Drugs; 2006 Jul; 17(6):631-9. PubMed ID: 16917208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors.
    Gyurkocza B; Plescia J; Raskett CM; Garlick DS; Lowry PA; Carter BZ; Andreeff M; Meli M; Colombo G; Altieri DC
    J Natl Cancer Inst; 2006 Aug; 98(15):1068-77. PubMed ID: 16882944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications.
    Pastorino F; Brignole C; Marimpietri D; Di Paolo D; Zancolli M; Pagnan G; Ponzoni M
    Ann N Y Acad Sci; 2004 Dec; 1028():90-103. PubMed ID: 15650235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging treatments in acute myeloid leukaemia.
    Kell J
    Expert Opin Emerg Drugs; 2004 May; 9(1):55-71. PubMed ID: 15155136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.